Document:

Nebido Contingent Cash Consideration Agreement

 Exhibit 10.54 
  
  
  
 NEBIDO 
 CONTINGENT CASH CONSIDERATION
AGREEMENT 
 by and between 
 ENDO
PHARMACEUTICALS HOLDINGS INC. 
 and 
 AMERICAN STOCK TRANSFER & TRUST COMPANY 
 as 
 Paying Agent 
  
  
 Dated as of February 23,
2009 
  
  
  
  
  

 TABLE OF CONTENTS 
  

					
	 	  	 	  	Page
	Section 1.	  	Appointment of Paying Agent	  	2
	Section 2.	  	No Certificates	  	2
	Section 3.	  	Registration by the Paying Agent	  	2
	Section 4.	  	Rights of Nebido CCCP Holder	  	3
	Section 5.	  	Non-transferability	  	3
	Section 6.	  	Transfer of Nebido CCCPs	  	3
	Section 7.	  	Payment Procedures	  	4
	Section 8.	  	Notices to the Company and Paying Agent	  	11
	Section 9.	  	Supplements and Amendments; Actions	  	12
	Section 10.	  	Enforcement of Rights of Holders	  	14
	Section 11.	  	Company May Consolidate, Etc.	  	14
	Section 12.	  	Certain Rights of the Paying Agent	  	15
	Section 13.	  	Designation; Removal; Successor Paying Agent	  	17
	Section 14.	  	Successors	  	18
	Section 15.	  	Termination; Effect of Termination	  	18
	Section 16.	  	Governing Law	  	19
	Section 17.	  	Benefits of this Agreement	  	19
	Section 18.	  	Counterparts	  	19
	Section 19.	  	Headings	  	19
	Section 20.	  	Additional Covenants	  	19
	Section 21.	  	Negotiation; Arbitration	  	20

  

 i 

 INDEX OF DEFINED TERMS 
  

			
	 Agreement
	  	1
	 Approval Deadline
	  	5
	 Approval Non-Compliance Certificate
	  	9
	 Approval With Label Compliance Certificate
	  	4, 6
	 Approval With Label Milestone
	  	5
	 Approval With Label Milestone Date
	  	5
	 Approval With Label Payment Amount
	  	5
	 Approval Without Label Compliance Certificate
	  	5
	 Approval Without Label Milestone
	  	6
	 Approval Without Label Milestone Date
	  	6
	 Approval Without Label Payment Amount
	  	6
	 Board Resolution
	  	12
	 Company
	  	1
	 Co-Paying Agents
	  	2
	 Determinations
	  	11
	 Effective Time
	  	1
	 Escrow Amount
	  	1
	 FDA
	  	5
	 Holder
	  	2
	 IFRS
	  	8
	 Indevus
	  	1
	 Indevus Common Stock
	  	1
	 Merger
	  	1
	 Merger Agreement
	  	1
	 Merger Sub
	  	1
	 Nebido CCCP
	  	1
	 Net Sales
	  	7
	 Net Sales Milestone
	  	6
	 Net Sales Milestone Date
	  	6
	 Net Sales Non-Compliance Certificate
	  	9
	 Net Sales Payment Amount
	  	7
	 Non-Compliance Certificate
	  	9
	 Notice of Objection
	  	10
	 Offer
	  	1
	 Offer Closing
	  	1
	 Paying Agent
	  	1
	 Payment Amounts
	  	11
	 Permitted Transfer
	  	3
	 Release Date
	  	4
	 Surviving Person
	  	13
	 Termination Date
	  	6

  

 ii 

 This NEBIDO CONTINGENT CASH CONSIDERATION AGREEMENT (this “Agreement”), dated as of
February 23, 2009, is entered into by and between Endo Pharmaceuticals Holdings Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, as Paying Agent (the “Paying
Agent”). 
 W I T N E S S E T H: 
 WHEREAS, the Company, BTB Purchaser Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Indevus Pharmaceuticals, Inc., a Delaware corporation
(“Indevus”), have entered into an Agreement and Plan of Merger, dated as of January 5, 2009 (as may be amended and restated from time to time, the “Merger Agreement”), pursuant to which, among other things,
Merger Sub has commenced an offer (as it may be amended from time to time as permitted under the Merger Agreement, the “Offer”) to purchase all of the outstanding shares of common stock, par value $0.001 per share, of Indevus (the
“Indevus Common Stock”), and, at the Effective Time (as defined in the Merger Agreement), Merger Sub will be merged (the “Merger”) with and into Indevus, with Indevus continuing as the surviving corporation and as a
wholly-owned subsidiary of the Company; 
 WHEREAS, the consideration to be paid for each share of Indevus Common Stock by Merger Sub in the
Offer and pursuant to the Merger Agreement includes contingent consideration payments as hereinafter described (each, a “Nebido CCCP” and collectively, the “Nebido CCCPs”); 
 WHEREAS, each holder of Indevus Common Stock who tenders Indevus Common Stock in the Offer or who is entitled to receive the Merger Consideration (as
defined in the Merger Agreement) will also receive one or more Nebido CCCPs in consideration for such holder’s shares of Indevus Common Stock in the amounts and subject to the terms and conditions set forth herein; 
 WHEREAS, all things necessary have been done to make the obligations of the Company hereunder the valid obligations of the Company, and to make this
Agreement a valid agreement of the Company, in accordance with its terms; 
 WHEREAS, at the Offer Closing (as defined in the Merger
Agreement, the “Offer Closing”), the Company will deposit $175,000,000 in cash (the “Escrow Amount”) with the Paying Agent, which amount is equal to the aggregate Approval With Label Payment Amount (as defined
below) payable upon the occurrence of the Approval With Label Milestone Date (as defined below), to be held and disposed of by the Paying Agent in accordance with this Agreement; and 
  

 1 

 WHEREAS, the Company desires the Paying Agent to act on behalf of the Company, and the Paying Agent is
willing to make payments in satisfaction of the Company’s obligations with respect to the Nebido CCCPs as provided herein. 
 NOW,
THEREFORE, in consideration of the premises and mutual agreements herein, the Company and the Paying Agent hereby agree as follows: 
 Section 1. Appointment of Paying Agent. The Company hereby appoints American Stock Transfer & Trust Company as the Paying Agent to act as agent for the Company in accordance with the instructions hereinafter set forth
in this Agreement, and the Paying Agent hereby accepts such appointment. The Company may from time to time appoint additional paying agents (“Co-Paying Agent(s)”) as it may deem necessary or desirable. The Paying Agent shall have no
duty to supervise, and shall in no event be liable for, the acts or omissions of any such Co-Paying Agents. In the event of the appointment of a Co-Paying Agent pursuant to this Section 1, the Company shall cause such Co-Paying Agent to become
vested with the same powers, rights, duties and responsibilities as if it had originally been named as Paying Agent. 
 Section 2. No
Certificates. The Nebido CCCPs shall not be evidenced by a certificate or other instrument. 
 Section 3. Registration by the
Paying Agent. 
 (a) The Company and the Paying Agent may deem and treat the registered holder (the “Holder”) of a Nebido
CCCP as the absolute owner thereof for all purposes, and neither the Company nor the Paying Agent shall be affected by any notice to the contrary. 
 (b) The Company shall cause to be kept at the Paying Agent’s principal office a register (the “Nebido CCCP Register”) in which the Paying Agent shall provide for the registration of the Nebido CCCPs. The Nebido CCCPs
shall be registered in the names and addresses of, and in the denomination as set forth in, the applicable letter of transmittal accompanying the shares of Indevus Common Stock surrendered by the holder thereof in connection with the Offer or the
Merger pursuant to the Merger Agreement. A Holder may make a written request to the Paying Agent or the Company to change such Holder’s address of record on the Nebido CCCP Register. The written request must be duly executed by the Holder. Upon
receipt of such written request by the Paying Agent or the Company, the Paying Agent shall promptly record the change of address on the Nebido CCCP Register. The Paying Agent shall provide a copy of the Nebido CCCP Register to the Company upon
request. 
  

 2 

 Section 4. Rights of Nebido CCCP Holder. Nothing contained in this Agreement shall be
construed as conferring upon any Holder, by virtue of being a Holder of a Nebido CCCP, the right to vote or to consent or to receive notice as stockholders in respect of the meetings of stockholders or the election of directors of the Company or any
other matter, or any rights of any kind or nature whatsoever as a stockholder of the Company, either at law or in equity. The rights of a Holder are limited to those expressed in this Agreement. 
 Section 5. Non-transferability. The Nebido CCCPs and any interest therein shall not be sold, assigned, transferred, pledged, encumbered or in
any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer (as defined herein) and, in the case of a Permitted Transfer, only in accordance with Section 6 hereof. A “Permitted
Transfer” shall mean (a) the transfer of any or all of the Nebido CCCPs on death, by will or intestacy; (b) transfer by instrument to an inter vivos or testamentary trust in which the Nebido CCCPs are to be passed to beneficiaries
upon the death of the trustee; (c) transfers made pursuant to a court order of a court of competent jurisdiction (such as in connection with divorce, bankruptcy or liquidation); (d) if the Holder is a partnership or limited liability
company, a distribution by the transferring partnership or limited liability company to its partners or members, as applicable; or (e) a transfer made by operation of law (such as a merger). 
 Section 6. Transfer of Nebido CCCPs. 
 (a) Subject to the restrictions on transferability set forth in Section 5 hereof, the Paying Agent shall, from time to time, register the transfer of any outstanding Nebido CCCPs upon the Nebido CCCP Register, upon delivery to the
Paying Agent of a written instrument or instruments of transfer and other requested documentation in a form satisfactory to the Company and the Paying Agent, duly executed by the registered Holder or Holders thereof or by the duly appointed legal
representative thereof or by a duly authorized attorney, such signature to be guaranteed by a participant in a recognized Signature Guarantee Medallion Program. A request for a transfer of a Nebido CCCP shall be accompanied by such documentation
establishing satisfaction of the conditions set forth in Section 5 hereof as may be reasonably requested by the Company (including opinions of counsel, if appropriate). Upon receipt of documentation reasonably satisfactory to the Company, the
Company shall authorize the Paying Agent to permit the transfer of a Nebido CCCP. The Paying Agent shall not permit the transfer of a Nebido CCCP until it is so authorized by the Company. No transfer of a Nebido CCCP shall be valid until registered
on the Nebido CCCP Register and any transfer not duly registered on the Nebido CCCP Register will be void ab initio. All transfers of Nebido CCCPs registered on the Nebido CCCP Register shall be the valid obligations of the Company,
representing the same rights to receive cash as the Nebido CCCPs 

  

 3 

 
transferred then entitled such transferee to receive, and shall entitle the transferee to the same benefits and rights under this Agreement as those held by
the transferor. It is clarified that the Nebido CCCP Register will show one position for Cede & Co which represents all the Shares held by DTC on behalf of the street holders of the Shares as of the Effective Time and the Paying Agent will
have no responsibility whatsoever directly to the street holders with respect to the transfer of Nebido CCCPs. It is also clarified that with respect to any payments to be made under Section 7 below, the Paying Agent will accomplish the payment
to the street holders by sending one lump payment to DTC, who will then be required to distribute the payments to brokers and shareholders as of the Effective Time. The Paying Agent will have no responsibilities whatsoever with regards to
distribution of payments to the street holders directly. 
 (b) No service charge shall be made for any registration of transfer of Nebido
CCCPs. The Paying Agent shall have no duty or obligation to take any action under any Section of this Agreement which requires the payment by a Holder of a Nebido CCCP of applicable taxes and charges unless and until the Paying Agent is satisfied
that all such taxes and/or charges have been paid. 
 Section 7. Payment Procedures. 
 (a) Escrow Amount. 
 (i) Any amounts payable to any Holder pursuant to this Agreement shall be paid first out of the Escrow Amount to the extent of the then remaining Escrow Amount. 
 (ii) If the Approval With Label Milestone Date or the Approval Without Label Milestone Date (each as defined below) shall have occurred,
on the payment date set forth in any certificate delivered pursuant to Section 7(b)(i) or Section 7(c)(i) hereof, as applicable, and following the payment of the Approval With Label Payment Amount or the Approval Without Label Payment
Amount (each as defined below), as applicable, in accordance with this Section 7, the Paying Agent shall deliver the then remaining Escrow Amount to the Company free and clear of any interest of any Holder. 
 (iii) Notwithstanding any other provision in this Agreement, on December 15, 2009 (the “Release Date”), the Paying
Agent shall deliver the then remaining Escrow Amount to the Company free and clear of any interest of any Holder; provided, however, that such delivery shall not limit or otherwise act to 

  

 4 

 
diminish the obligations of the Company hereunder, including, without limitation, any obligations to pay any amounts to Holders if and when payable.

 (b) Approval With Label. 
 (i) Within 5 business days following the occurrence of the Approval With Label Milestone Date, the Company shall deliver to the Paying Agent (A) a certificate (the “Approval With Label Compliance
Certificate”) certifying that the Holders are entitled to receive the Approval With Label Payment Amount and establishing a payment date with respect to the Approval With Label Payment Amount that is within 5 business days of the date of
the issuance of such certificate and (B) if the Release Date shall have occurred, an amount in cash equal to the aggregate Approval With Label Payment Amount with respect to Nebido CCCPs held by all Holders. Upon payment of such aggregate
Approval With Label Payment Amount, no further payment by the Company pursuant to this Agreement shall be required. 
 (ii)
“Approval With Label Milestone Date” shall mean the date on which the Company (or any of its subsidiaries) receives an approval letter from the U.S. Food and Drug Administration (the “FDA”) with respect to its new
drug application for Nebido (as defined in the Merger Agreement), which approval letter grants the Company the right to market and sell Nebido immediately and provides labeling for Nebido that does not contain a “boxed warning” (as defined
in 21 CFR 201.57(c)(1)) (the “Approval With Label Milestone”); provided, however, that, subject to Section 7(l) hereof, if the Approval With Label Milestone Date does not occur on or before the third anniversary
of the Offer Closing (the “Approval Deadline”), the Nebido CCCPs will terminate and all rights thereunder and all rights in respect thereof under this Agreement shall cease; provided, further, that in no event shall
the Approval With Label Milestone Date occur if the Approval Without Label Milestone Date shall have already occurred. 
 (iii) “Approval With Label Payment Amount” means an amount equal to $2.00 per Nebido CCCP, without interest thereon, payable in cash. 
  

 5 

 (c) Approval Without Label. 
 (i) Within 5 business days following the occurrence of the Approval Without Label Milestone Date, the Company shall deliver to the Paying
Agent (A) a certificate (the “Approval Without Label Compliance Certificate”) certifying that the Holders are entitled to receive the Approval Without Label Payment Amount and establishing a payment date with respect to the
Approval Without Label Payment Amount that is within 5 business days of the date of such certificate and (B) if the Release Date shall have occurred, an amount in cash equal to the aggregate Approval Without Label Payment Amount with respect to
Nebido CCCPs held by all Holders. 
 (ii) “Approval Without Label Milestone Date” shall mean the date on
which the Company (or any of its subsidiaries) receives an approval letter from the FDA with respect to its new drug application for Nebido (as defined in the Merger Agreement), which approval letter grants the Company the right to market and sell
Nebido immediately and provides labeling for Nebido that contains a “boxed warning” (as defined in 21 CFR 201.57(c)(1)) (the “Approval Without Label Milestone”); provided, however, that, subject to
Section 7(l) hereof, if the Approval Without Label Milestone Date does not occur on or before the Approval Deadline, the Nebido CCCPs will be terminated and all rights thereunder and all rights in respect thereof under this Agreement shall
cease; provided, further, that in no event shall the Approval Without Label Milestone Date occur if the Approval With Label Milestone Date shall have already occurred. 
 (iii) “Approval Without Label Payment Amount” means an amount equal to $1.00 per Nebido CCCP, without interest thereon,
payable in cash. 
 (iv) If the Approval Without Label Milestone Date shall have occurred, within 5 business days following
the occurrence of the Net Sales Milestone Date, the Company shall, at such time, deliver to the Paying Agent (A) a certificate (the “Net Sales Compliance Certificate”) certifying that the Holders are entitled to receive the Net
Sales Payment Amount and establishing a payment date with respect to the Net Sales Payment Amount that is within 5 business days of the date of such certificate and (B) an amount in cash equal to the aggregate Net Sales Payment Amount with
respect to the Nebido CCCPs held by all Holders. Upon such payment, no further payment by the Company pursuant to this Agreement shall be required. 
  

 6 

 (v) “Net Sales Milestone Date” shall mean the date following the
Approval Without Label Milestone Date on which the Company (and its subsidiaries) publicly report audited financial statements which reflect at least $125,000,000 in cumulative Net Sales during any four consecutive calendar quarters ending on or
prior to the fifth anniversary of the date of first commercial sale of Nebido (the achievement of such Net Sales in such time period, the “Net Sales Milestone” and such fifth anniversary, the “Termination Date”).

 (vi) “Net Sales Payment Amount” means an amount equal to $1.00 per Nebido CCCP, without interest thereon,
payable in cash. 
 (vii) “Net Sales” means, with respect to Nebido, the gross amount invoiced by or on
behalf of the Company or its affiliates, licensees or sublicensees for Nebido sold to third parties other than licensees or sublicensees in bona fide, arm’s-length transactions, less the following deductions, determined in accordance with the
Company’s standard accounting methods as generally and consistently applied by the Company, to the extent included in the gross invoiced sales price of the product or otherwise directly paid or incurred by the Company, its affiliates, licensees
or sublicensees acting on its behalf with respect to the sale of such product: 
 (1) normal and customary trade and quantity
discounts actually allowed and properly taken directly with respect to sales of the product; 
 (2) amounts repaid or
credited by reasons of defects, recalls, returns, rebates and allowances of goods or because of retroactive price reductions specifically identifiable to the product; 
 (3) chargebacks, rebates (or the equivalent thereof) and other amounts paid on sale or dispensing of the product; 
 (4) rebates (or the equivalent thereof) and administrative fees paid to medical healthcare organizations, to 

  

 7 

 
group purchasing organizations or to trade customers in line with approved contract terms or other normal and customary understandings and arrangements;

 (5) amounts payable resulting from governmental (or agency thereof) mandated rebate programs or chargeback programs;

 (6) tariffs, duties, excise, sales, value-added and other taxes (other than taxes based on income) and charges of
Governmental Authorities; 
 (7) cash discounts for timely payment; 
 (8) rebates paid to wholesalers for inventory management programs; 
 (9) amounts repaid or credited or provisions made for uncollectible amounts on previously sold products; and 
 (10) required distribution commissions and fees (such as fees related to services provided pursuant to distribution service agreements
with major wholesalers) payable to any third party providing distribution services to the Company so long as such commissions and fees are consistent with the distribution commissions and fees payable in respect to other branded prescription
products commercialized by the Company; 
 all as determined in accordance with the Company’s usual and customary accounting methods,
which shall be in accordance with U.S. Generally Accepted Accounting Principles; or in accordance with International Financial Reporting Standards (“IFRS”), should the Company be required to, or elect to maintain records and books
of accounts in accordance with IFRS. Sales from the Company to its affiliates, licensees or sublicensees shall be disregarded for purposes of calculating Net Sales. Any of the items set forth above that would otherwise be deducted from the invoice
price in the calculation of Net Sales but which are charged to third parties shall not be deducted from the invoice price in the calculation of Net Sales. Further: 
 (1) In the case of any sale or other disposal of a product between or among the Company and its affiliates, licensees and sublicensees,
for resale, Net Sales shall be calculated as above only on the value charged or invoiced on the first arm’s-length sale thereafter to a third party; 
  

 8 

 (2) In the case of any sale which is not invoiced or is delivered before invoice, Net
Sales shall be calculated at the time of shipment or when the product is paid for, if paid for before shipment or invoice; and 
 (3) In the case of any sale or other disposal for value, such as barter or counter-trade, of any product, or part thereof, other than in an arm’s-length transaction exclusively for money and excluding any patient assistance programs,
Net Sales shall be calculated as above on the value of the non-cash consideration received or the fair market price (if higher) of the product in the country of sale or disposal. 
 (d) If (A) prior to the delivery of an Approval With Label Compliance Certificate or an Approval Without Label Compliance Certificate, events or
circumstances occur that cause the Company reasonably to believe that either or both of the Approval With Label Milestone Date or the Approval Without Label will not and cannot occur prior to the Approval Deadline or, (B) an approval of Nebido
is obtained but the Company determines that it does not meet the definition of an Approval With Label Milestone or Approval Without Label Milestone, then within 30 days of the occurrence of such events or circumstances or determination, the Company
shall deliver to the Paying Agent a certificate (the “Approval Non-Compliance Certificate”) setting forth in reasonable detail the events and circumstances underlying its belief that delivery of such Non-Compliance Certificate is
required. 
 (e) If, after the delivery of an Approval Without Label Compliance Certificate, on the Termination Date the Net Sales Milestone
has not occurred, the Company shall, promptly after such time, deliver to the Paying Agent a certificate (the “Net Sales Non-Compliance Certificate”) setting forth such fact. Each of the Approval Non-Compliance Certificate and the
Net Sales Non-Compliance Certificate is referred to herein as a “Non-Compliance Certificate”. 
 (f) On the applicable
payment date, the Paying Agent shall pay the applicable amount to each of the Holders (the amount to which each Holder is entitled to receive will be based on the number of Nebido CCCPs held by such Holder as reflected on the Nebido CCCP Register)
by (i) check mailed to the address of each Holder as reflected on the Nebido CCCP Register as of the close of business on the last business day prior to such payment date or (ii) with respect to Holders that are due amounts in excess of
$1,000,000 in the aggregate who have provided the 

  

 9 

 
Company with wire transfer instructions in writing, the Paying Agent will make payments by wire transfer of immediately available funds to the account
specified in the written instructions of the Company. In addition to the notices required by Section 11 hereof, the Company shall cause the Paying Agent, on behalf of and at the expense of the Company, to mail with (or, in the case of payments
made to Holders who have provided the Company with wire instructions, at the same time as) each payment made a copy of each Compliance Certificate (whether the Approval With Label Compliance Certificate, Approval Without Label Compliance Certificate
or a Net Sales Compliance Certificate) to which such payment relates. In addition, the Company shall post a copy of such Compliance Certificate on its Internet website and issue a press release announcing the occurrence of the applicable milestone
date. 
 (g) The Company shall cause the Paying Agent to promptly (and in no event later than five business days after receipt by the Paying
Agent) send each Holder a copy of each Non-Compliance Certificate at such Holder’s registered address. 
 (h) The Company shall be
entitled to deduct and withhold, or cause to be deducted or withheld, from any amounts otherwise payable pursuant to this Agreement, such amounts as it is required to deduct and withhold with respect to the making of such payment under the Internal
Revenue Code, or any provision of state, local or foreign tax law. To the extent that amounts are so withheld or paid over to or deposited with the relevant governmental entity, such withheld amounts shall be treated for all purposes of this
Agreement as having been paid to the Holder in respect of which such deduction and withholding was made. 
 (i) The Paying Agent shall invest
any cash held by it for payment to the Holders, including the Escrow Amount, in a JP Morgan Custodial Account or as reasonably directed by the Company in writing. Any interest and other income resulting from such investment shall promptly be paid to
the Company. 
 (j) Any cash that remains undistributed to the Holders of Nebido CCCPs six months after the payment date set forth in any
Approval With Label Compliance Certificate, Approval Without Label Compliance Certificate or Net Sales Compliance Certificate, as applicable, shall be delivered to the Company, upon demand, and any Holders of Nebido CCCPs who have not theretofore
received cash in exchange for such Nebido CCCPs shall thereafter look only to the Company for payment of their claim therefor. Notwithstanding any other provisions of this Agreement, any portion of the cash provided by the Company to the Paying
Agent that remains unclaimed after termination of this Agreement in accordance with Section 15 hereof (or such earlier date immediately prior to such time as such amounts would otherwise escheat to, or become property of, any governmental
entity) shall, to the extent permitted by law, become the property of the Company free and clear of any claims or interest of any person previously entitled thereto. 
  

 10 

 (k) The Paying Agent shall keep copies of this Agreement available for inspection by the Holders during
normal business hours at its office. The Company shall supply the Paying Agent from time to time with such numbers of copies of this Agreement as the Paying Agent may request. 
 (l) Any Holder or Holders of at least 20% in the aggregate of the outstanding Nebido CCCPs may, within 45 days of (A) receipt of any Non-Compliance
Certificate or (B) the payment of the Approval Without Label Payment Amount, deliver a written notice to the Paying Agent and the Company stating that such Holder or Holders object to (a “Notice of Objection”) such
Non-Compliance Certificate or nonpayment of the Approval With Label Amount (as applicable) and setting forth in reasonable detail each of the objections to the events or circumstances described in the applicable Non-Compliance Certificate or the
failure to pay the Approval With Label Payment Amount (as applicable) (collectively, the “Determinations”). If the Company does not agree with the objections to the applicable Non-Compliance Certificate in the Objection Certificate,
the Determinations that are in dispute shall be resolved by the procedure set forth in Section 21, which decision shall be binding on the parties hereto and the Holders. If no Notice of Objection is delivered to the Paying Agent within such 45
day period, the applicable Approval With Label Payment Amount, Approval Without Label Payment Amount, or Net Sales Payment Amount (collectively, “Payment Amounts”) to which the Non-Compliance Certificate relates, or, in the case of
the payment of the Approval Without Label Payment Amount, the Approval With Label Payment Amount, shall not be due and payable to the Holders, and the Company and the Paying Agent shall have no further obligations with respect to such Payment Amount
(but may have obligations with respect to the other Payment Amounts in accordance with the terms of this Agreement). 
 Section 8.
Notices to the Company and Paying Agent. Any notice or demand authorized by this Agreement to be given or made by the Paying Agent or by any Holder to or on the Company shall be sufficiently given or made when received at the office of the
Company expressly designated by the Company as its office for purposes of this Agreement (until the Paying Agent is otherwise notified in accordance with this Section 8 by the Company), as follows: 
 Endo Pharmaceuticals Holdings Inc. 
 100 Endo
Boulevard 
 Chadds Ford, PA 19317 
 Fax No.: (610) 558-9864 
 Attention: Caroline B. Manogue, Esq. 
  

 11 

 and with a copy to: 
 Skadden, Arps, Slate, Meagher & Flom LLP 
 Four Times Square 
 New York, New York 10036-6522 
 Fax No.:
(212) 735-2000 
 Attention: Eileen T. Nugent, Esq. 
 Any notice pursuant to this Agreement to be given by the Company or by any Holder(s) to the Paying Agent shall be sufficiently given when received by the Paying Agent at the address appearing below (until the Company
is otherwise notified in accordance with this Section 8 by the Paying Agent). 
 American Stock Transfer & Trust Company LLC

 Operations Center 
 6201 15th
Avenue 
 Brooklyn, NY 11219 
 Telephone: (800) 937-5449 
 Attention: Reorganization Department 
 Section 9. Supplements and Amendments; Actions. 
 (a) Without the consent of any Holders, the Company, at any time and from time to time, may enter into one or more amendments hereto, for any of the following purposes: 
 (i) to evidence the succession of another person to the Company and the assumption by any such successor of the covenants of the Company
herein; provided that such succession and assumption is in accordance with the terms of this Agreement; 
 (ii) to
evidence the succession of another person as a successor Paying Agent and the assumption by any successor of the covenants and obligations of such Paying Agent herein; provided that such succession and assumption is in accordance with the
terms of this Agreement; 
 (iii) to add to the covenants of the Company such further covenants, restrictions, conditions or
provisions as the Company shall consider to be for the protection of Holders; provided that in each case, such provisions shall not adversely affect the rights of the Holders; or 
  

 12 

 (iv) to cure any ambiguity, to correct or supplement any provision herein that may be
defective or inconsistent with any other provision herein, or to make any other provisions with respect to matters or questions arising under this Agreement; provided that in each case, such provisions shall not adversely affect the rights of
Holders. 
 (b) Subject to Section 9(c) hereof, with the written consent of the Holders of not less than a majority of the then
outstanding and unpaid Nebido CCCPs delivered to the Company, the Company (when authorized by a Board Resolution (as defined below)) may enter into one or more amendments hereto for the purpose of adding, eliminating or changing any provision of
this Agreement, if such addition, elimination or change is in any way adverse to the rights of Holders. It shall not be necessary for any written consent of Holders under this Section 9(b) to approve the particular form of any proposed
amendment, but it shall be sufficient if such written consent shall approve the substance thereof. “Board Resolution” means a resolution, certified by the secretary or an assistant secretary of the Company to have been duly adopted
by the Board of Directors and to be in full force and effect on the date of such certification, and delivered to the Paying Agent. 
 (c) The
unanimous consent of each and every Holder affected shall be required for any amendment pursuant to which the amount of cash payable in consideration for the Nebido CCCPs would be decreased. 
 (d) Promptly after the execution by the Company of any amendment pursuant to the provisions of this Section 9, the Company shall mail by first class
mail, postage prepaid, a notice thereof to the Holders at their addresses as they shall appear on the Nebido CCCP Register, setting forth in general terms the substance of such amendment. 
 (e) Upon the execution of any amendment in accordance with this Section 9, this Agreement shall be modified in accordance therewith, such amendment
shall form a part of this Agreement for all purposes and every Holder shall be bound thereby. 
 (f) The Paying Agent shall be entitled to
receive and shall be fully protected in relying upon an officers’ certificate and opinion of counsel as conclusive evidence that any such amendment or supplement is authorized or permitted hereunder, that it is not inconsistent herewith, and
that it will be valid and binding upon the Company in accordance with its terms. 
  

 13 

 Section 10. Enforcement of Rights of Holders. Any actions seeking enforcement of the rights
of Holders hereunder may be brought either by the Paying Agent or the Holders of a majority of outstanding and unpaid Nebido CCCPs. 
 Section 11. Company May Consolidate, Etc. 
 (a) The Company shall not consolidate with or merge into any other Person
(as defined in the Merger Agreement) or convey, transfer or lease its properties and assets substantially as an entirety to any Person, unless: 
 (i) The board of directors of the Company shall have determined that, following such transaction, such Person would reasonably be expected to be able to carry out the obligations of the Company hereunder; 

(ii) the Person formed by such consolidation or into which the Company is merged or the Person that acquires by conveyance or transfer,
or that leases, the properties and assets of the Company substantially as an entirety (the “Surviving Person”) shall, by a supplemental contingent consideration payment agreement or other acknowledgment executed and delivered to the
Paying Agent, expressly assume payment of amounts on all the Nebido CCCPs and the performance of every duty, obligation liability and covenant of this Agreement, subject to the conditions herein, on the part of the Company to be performed or
observed in the manner prescribed herein; and 
 (iii) the Company has delivered to the Paying Agent a Certificate executed by
the Chief Executive Officer of the Company, stating that such consolidation, merger, conveyance, transfer or lease complies with this Section 11 and that all conditions precedent herein provided for relating to such transaction have been
complied with. 
 (b) Upon any consolidation of or merger by the Company with or into any other Person, or any conveyance, transfer or lease
of the properties and assets substantially as an entirety to any Person in accordance with Section 11(a) hereof, the Surviving Person shall succeed to, and be substituted for, and may exercise every right and power of, the Company under this
Agreement with the same effect as if the Surviving Person had been named as the Company herein, and thereafter, except in the case of a lease, the predecessor Person shall be relieved of all obligations and covenants under this Agreement and the
Nebido CCCPs. 
  

 14 

 (c) In the event that (i) the Company shall enter into any definitive agreement with respect to a
consolidation or merger (whether by proxy, tender offer or otherwise) involving the Company and for which approval of stockholders of the Company is required, or of the conveyance or transfer of the properties and assets of the Company substantially
as an entirety, or a tender offer or exchange offer for shares of its common stock; or (ii) the Company shall file (or have filed against it) for the voluntary or involuntary dissolution, liquidation or winding up of the Company, then the
Company shall give prompt written notice to the Paying Agent and shall cause the Paying Agent, on behalf of and at the expense of the Company to give to each Holder of a Nebido CCCP at his, her or its address appearing on the Nebido CCCP Register,
at least 10 days prior to the applicable record date for such transaction, or the date of the event in the case of events for which there is no record date, by first-class mail, postage prepaid, a written notice stating (i) the date on which
any such consolidation, merger, conveyance, transfer, dissolution, liquidation or winding up is reasonably expected to become effective or consummated or (ii) the initial expiration date set forth in any tender offer or exchange offer for
shares of the Company’s common stock. The failure by the Company or the Paying Agent to give such notice or any defect therein shall not affect the legality or validity of any consolidation, merger, conveyance, transfer, dissolution,
liquidation or winding up, or the vote upon any such action. 
 (d) The provisions of this Section 11 shall apply to successive
transactions. 
 Section 12. Certain Rights of the Paying Agent. The Paying Agent undertakes the duties and obligations imposed
by this Agreement upon the following terms and conditions, by all of which the Company and the Holders, by their acceptance of the Nebido CCCPs, shall be bound: 
 (a) The statements contained herein and in any notice delivered by the Company shall be taken as statements of the Company, and the Paying Agent assumes no responsibility for the correctness of any of the same except
such as describe the Paying Agent or any action taken by it. The Paying Agent assumes no responsibility with respect to the distribution of the Nebido CCCPs except as herein otherwise provided. 
 (b) The Paying Agent shall not be responsible for any failure of the Company to comply with the covenants contained in this Agreement to be complied with
by the Company. The Paying Agent shall not be responsible for the failure of the Company to issue any certificate required under this Agreement or to determine whether such certificate is required or for the contents of any certificate issued by the
Company. 
  

 15 

 (c) The Paying Agent may execute and exercise any of the rights or powers hereby vested in it or perform
any duty hereunder either by itself (through its employees) or by or through its attorneys or agents (which shall not include its employees) and shall not be responsible for the misconduct of any agent appointed with due care. 
 (d) The Paying Agent may consult at any time with legal counsel satisfactory to it (who may be counsel for the Company), and the Paying Agent shall incur
no liability or responsibility to the Company or to any Holder in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with the opinion or the advice of such counsel. 
 (e) Whenever in the performance of its duties under this Agreement the Paying Agent shall deem it necessary or desirable that any fact or matter be
proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless such evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a
certificate signed by the Chairman of the Board, the Chief Executive Officer, the President, the Chief Financial Officer, one of the Vice Presidents, the Treasurer or the Secretary of the Company and delivered to the Paying Agent; and such
certificate shall be full authorization to the Paying Agent for any action taken or suffered in good faith by it under the provisions of this Agreement in reliance upon such certificate. 
 (f) The Company agrees to pay the Paying Agent reasonable compensation for all services rendered by the Paying Agent in the performance of its duties
under this Agreement, to reimburse the Paying Agent for all expenses, taxes and governmental charges and other charges of any kind and nature incurred by the Paying Agent (including reasonable fees and expenses of the Paying Agent’s counsel and
agents) in the performance of its duties under this Agreement, and to indemnify the Paying Agent and save it harmless against any and all liabilities, including judgments, costs and counsel fees, for anything done or omitted by the Paying Agent in
the performance of its duties under this Agreement, except as a result of the Paying Agent’s gross negligence or bad faith. 
 (g) The
Paying Agent shall be under no obligation to institute any action, suit or legal proceeding or to take any other action likely to involve expense unless the Company or one or more Holders shall furnish the Paying Agent with reasonable security and
indemnity satisfactory to the Paying Agent for any costs and expenses which may be incurred, but this provision shall not affect the power of the Paying Agent to take such action as the Paying Agent may consider proper, whether with or without any
such security or indemnity. All rights of action under this Agreement may be enforced by the Paying Agent, and any such action, suit or proceeding instituted by the Paying Agent shall be brought in its name as Paying Agent, and any recovery of
judgment shall be for the ratable benefit of the Holders, as their respective rights or interests may appear. 
  

 16 

 (h) The Paying Agent and any stockholder, director, officer or employee of the Paying Agent may buy, sell
or deal in any other securities of the Company or become pecuniarily interested in any transactions in which the Company may be interested, or contract with or lend money to the Company or otherwise act as fully and freely as though it were not
Paying Agent under this Agreement or such director, officer or employee. Nothing herein shall preclude the Paying Agent from acting in any other capacity for the Company or for any other legal entity including, without limitation, acting as transfer
agent or as a lender to the Company or an affiliate thereof. 
 (i) The Paying Agent shall act hereunder solely as agent, and its duties
shall be determined solely by the provisions hereof. The Paying Agent shall not be liable for anything which it may do or refrain from doing in connection with this Agreement except for its own gross negligence or bad faith. 
 (j) The Paying Agent will not incur any liability or responsibility to the Company or to any Holder for any action taken in reliance on any notice,
resolution, waiver, consent, order, certificate, or other paper, document or instrument reasonably believed by it to be genuine and to have been signed, sent or presented by the proper party or parties. 
 (k) The Paying Agent shall not be under any responsibility in respect of the validity of this Agreement or the execution and delivery hereof (except the
due execution hereof by the Paying Agent) or in respect of the validity of any Nebido CCCP. 
 (l) The Paying Agent is hereby authorized and
directed to accept instructions with respect to the performance of its duties hereunder from the Chairman of the Board, the Chief Executive Officer President, the Chief Financial Officer, any Vice President or the Secretary of the Company, and to
apply to such officers for advice or instructions in connection with its duties, and shall not be liable for any action taken or suffered to be taken by it in good faith and without negligence in accordance with the instructions of any such officer
or officers. 
 Section 13. Designation; Removal; Successor Paying Agent. The Paying Agent may resign at any time and be
discharged from its duties under this Agreement by giving to the Company 30 days’ notice in writing. The Company may remove the Paying Agent or any successor Paying Agent by giving to the Paying Agent or successor Paying Agent 30 days’
notice in writing. If the Paying Agent shall resign or be removed or shall otherwise become incapable of acting, the 

  

 17 

 
Company shall appoint a successor to the Paying Agent. If the Company shall fail to make such appointment within a period of 30 days after such removal or
after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Paying Agent or by any Holder (whose name shall appear on the Nebido CCCP Register), then any Holder may apply to any court of competent
jurisdiction for the appointment of a successor to the Paying Agent. Pending appointment of a successor Paying Agent, either by the Company or by such court, the duties of the Paying Agent shall be carried out by the Company. Any successor Paying
Agent, whether appointed by the Company or such a court, shall be a bank or trust company in good standing, incorporated under the laws of the United States of America or any State thereof or the District of Columbia and having at the time of its
appointment as Paying Agent a combined capital and surplus of at least $10,000,000. After appointment, the successor Paying Agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named as Paying
Agent without further act or deed; but the former Paying Agent shall deliver and transfer to the successor Paying Agent any property at the time held by it hereunder, and execute and deliver any further assurance, conveyance, act or deed necessary
for such purpose. In the event of such resignation or removal, the Company or the successor Paying Agent shall mail by first class mail, postage prepaid, to each Holder, written notice of such removal or resignation and the name and address of such
successor Paying Agent. Failure to file any notice provided for in this Section 13, however, or any defect therein, shall not affect the legality or validity of the resignation or removal of the Paying Agent or the appointment of the successor
Paying Agent, as the case may be. 
 Section 14. Successors. All the covenants and provisions of this Agreement by or for the
benefit of the Company, the Paying Agent or any Holder shall bind and inure to the benefit of their respective successors, assigns, heirs and personal representatives. 
 Section 15. Termination; Effect of Termination. 
 (a) Subject to the resolution of any disputes
in accordance with Sections 7(l) and 21 hereof, in the event that the Approval With Label Milestone Date or the Approval Without Label Date shall not have occurred on or prior to the Approval Deadline, this Agreement shall terminate at 5:00 p.m.,
New York City time, on the Approval Deadline. 
 (b) In the event that the Approval With Label Milestone Date shall have occurred prior to
the Approval Deadline, this Agreement will terminate at 5:00 p.m., New York City time, on the date that all payments are sent by the Paying Agent in respect of the payment date set forth in any certificate delivered pursuant to Section 7(b)(i)
hereof. 
  

 18 

 (c) Subject to the resolution of any disputes in accordance with Sections 7(l) and 21 hereof, in the
event that the Approval Without Label Milestone Date shall have occurred prior to the Approval Deadline, this Agreement will terminate at 5:00 p.m., New York City time, on the earlier of (i) the date that all payments are sent by the Paying
Agent in respect of the payment date set forth in any certificate delivered pursuant to Section 7(c)(iv) hereof and (ii) the Termination Date. 
 (d) Notwithstanding anything to the contrary contained herein, the indemnification contained in Section 12(f) hereof shall survive termination of this Agreement. 
 (e) Upon termination of this Agreement, each Nebido CCCP shall become void, and all rights thereunder and all rights in respect thereof under this
Agreement shall cease. 
 Section 16. Governing Law. This Agreement shall be governed by, and construed in accordance with, the
laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflict of laws thereof. 
 Section 17. Benefits of this Agreement. Nothing in this Agreement shall be construed to give to any person or corporation other than the Company, the Paying Agent and the Holders any legal or equitable right, remedy or claim
under this Agreement; but this Agreement shall be for the sole and exclusive benefit of the Company, the Paying Agent and the Holders. 
 Section 18. Counterparts. This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each
of the parties and delivered to the other parties. 
 Section 19. Headings. The headings and table of contents contained in this
Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 
 Section 20. Additional Covenants 
 (a) List of Holders. The Company shall furnish or cause to be furnished to the
Paying Agent (a) in such form as the Company receives from its transfer agent (or other agent performing similar services for the Company), the names and addresses of the Holders within five business days of the Effective Time, and (b) at
such times as the Paying Agent may request in writing, within five business days after receipt by the Company of any such request, a list, in such form as the Company receives from its transfer agent (or other agent performing similar services for
the Company), of the names and the addresses of the Holders as of a date not more than 15 days prior to the time such list is furnished. 
  

 19 

 (b) Ability To Make Prompt Payment. Neither the Company nor any of its subsidiaries shall
enter into any agreement that would restrict the Company’s right to be able to promptly make or cause to be made payments to the Holders under this Agreement or otherwise restrict the Company’s ability to fund or cause to be funded such
payments. 
 Section 21. Negotiation; Arbitration. 
 (a) Prior to any arbitration pursuant to Section 21(b) hereof, the Company, the Paying Agent and any Holder or Holders of at least 20% in the aggregate of the outstanding Nebido CCCPs shall negotiate in good
faith for a period of 30 days to resolve any controversy or claim arising out of or relating to this Agreement, or the alleged breach thereof. 
 (b) After expiration of the 30-day period contemplated by Section 21(a) hereof, such controversy or claim, including any claims for breach of this Agreement, shall be settled by arbitration administered by the American Arbitration
Association under its Commercial Arbitration Rules, and judgment on the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. The Company, the Paying Agent and any Holder or Holders of at least 20% in the
aggregate of the outstanding Nebido CCCPs may initiate an arbitration for any matter relating to this Agreement. The number of arbitrators shall be three. Within 15 days after the commencement of arbitration, each party shall select one person to
act as arbitrator, and the two selected shall select a third arbitrator within 15 days of their appointment. If the arbitrators selected by the parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be selected by
the American Arbitration Association. The place of the arbitration shall be New York, New York, and the arbitration shall be conducted in such a manner so that the written opinion of the arbitrators is given within 180 days after the arbitrators are
selected. The arbitrators shall be lawyers or retired judges with experience in the life sciences industry and with mergers and acquisitions. Except as may be required by law, neither a party nor an arbitrator may disclose the existence, content or
results of any arbitration hereunder without the prior written consent of both parties. All fees and expenses incurred in connection with any arbitration, including the costs and expenses billed by the arbitrators in connection with the performance
of their duties described herein shall be paid by the party or parties against whom the arbitrators rule. 
  

 20 

 Any award payable in favor of the Holder or Paying Agent as a result of arbitration shall be distributed
to the Holders on a pro rata basis, based on the number of Nebido CCCPs held by each Holder. 
  

 21 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed, as of the day and
year first above written. 
  

			
	ENDO PHARMACEUTICALS HOLDINGS INC.
		
	By:	 	 /s/ David P. Holveck

	Name:	 	David P. Holveck
	Title:	 	CEO
	
	AMERICAN STOCK TRANSFER & TRUST COMPANY
	
	as Paying Agent
		
	By:	 	 /s/ Isaac Freilich

	Name:	 	Isaac Freilich
	Title:	 	VP

  

 22Octreotide Contingent Cash Consideration Agreement

 Exhibit 10.55 
  
  
  
 OCTREOTIDE 
 CONTINGENT CASH CONSIDERATION
AGREEMENT 
 by and between 
 ENDO
PHARMACEUTICALS HOLDINGS INC. 
 and 
 AMERICAN STOCK TRANSFER & TRUST COMPANY 
 as 
 Paying Agent 
  
  
 Dated as of February 23,
2009 
  
  
  
  
  

 TABLE OF CONTENTS 
  

					
	 	 	 	  	Page
	Section 1.	 	Appointment of Paying Agent	  	2
	Section 2.	 	No Certificates	  	2
	Section 3.	 	Registration by the Paying Agent	  	2
	Section 4.	 	Rights of Octreotide CCCP Holder	  	2
	Section 5.	 	Non-transferability	  	3
	Section 6.	 	Transfer of Octreotide CCCPs	  	3
	Section 7.	 	Payment Procedures	  	4
	Section 8.	 	Notices to the Company and Paying Agent	  	7
	Section 9.	 	Supplements and Amendments; Actions	  	8
	Section 10.	 	Enforcement of Rights of Holders	  	9
	Section 11.	 	Company May Consolidate, Etc.	  	9
	Section 12.	 	Certain Rights of the Paying Agent	  	11
	Section 13.	 	Designation; Removal; Successor Paying Agent	  	13
	Section 14.	 	Successors	  	14
	Section 15.	 	Termination; Effect of Termination	  	14
	Section 16.	 	Governing Law	  	14
	Section 17.	 	Benefits of this Agreement	  	14
	Section 18.	 	Counterparts	  	14
	Section 19.	 	Headings	  	15
	Section 20.	 	Additional Covenants	  	15
	Section 21.	 	Negotiation; Arbitration	  	15

  

 i 

 INDEX OF DEFINED TERMS 
  

			
	 Agreement
	  	1
	 Approval Compliance Certificate
	  	4
	 Approval Deadline
	  	4
	 Approval Milestone
	  	4
	 Approval Milestone Date
	  	4
	 Approval Non-Compliance Certificate
	  	4
	 Approval Payment Amount
	  	4
	 Board Resolution
	  	8
	 Company
	  	1
	 Co-Paying Agents
	  	2
	 Determinations
	  	6
	 Effective Time
	  	1
	 FDA
	  	4
	 Holder
	  	2
	 Indevus
	  	1
	 Indevus Common Stock
	  	1
	 Merger
	  	1
	 Merger Agreement
	  	1
	 Merger Sub
	  	1
	 Notice of Objection
	  	6
	 Octreotide CCCP
	  	1
	 Offer
	  	1
	 Paying Agent
	  	1
	 Permitted Transfer
	  	3
	 Surviving Person
	  	9

  

 ii 

 This OCTREOTIDE CONTINGENT CASH CONSIDERATION AGREEMENT (this “Agreement”), dated as of
February 23, 2009, is entered into by and between Endo Pharmaceuticals Holdings Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, as Paying Agent (the “Paying
Agent”). 
 W I T N E S S E T H: 
 WHEREAS, the Company, BTB Purchaser Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Indevus Pharmaceuticals, Inc., a Delaware corporation
(“Indevus”), have entered into an Agreement and Plan of Merger, dated as of January 5, 2009 (as may be amended and restated from time to time, the “Merger Agreement”), pursuant to which, among other things,
Merger Sub has commenced an offer (as it may be amended from time to time as permitted under the Merger Agreement, the “Offer”) to purchase all of the outstanding shares of common stock, par value $0.001 per share, of Indevus (the
“Indevus Common Stock”), and, at the Effective Time (as defined in the Merger Agreement), Merger Sub will be merged (the “Merger”) with and into Indevus, with Indevus continuing as the surviving corporation and as a
wholly-owned subsidiary of the Company; 
 WHEREAS, the consideration to be paid for each share of Indevus Common Stock by Merger Sub in the
Offer and pursuant to the Merger Agreement includes contingent consideration payments as hereinafter described (each, an “Octreotide CCCP” and collectively, the “Octreotide CCCPs”); 
 WHEREAS, each holder of Indevus Common Stock who tenders Indevus Common Stock in the Offer or who is entitled to receive the Merger Consideration (as
defined in the Merger Agreement) will also receive one or more Octreotide CCCPs in consideration for such holder’s shares of Indevus Common Stock in the amounts and subject to the terms and conditions set forth herein; 
 WHEREAS, all things necessary have been done to make the obligations of the Company hereunder the valid obligations of the Company, and to make this
Agreement a valid agreement of the Company, in accordance with its terms; 
 WHEREAS, the Company desires the Paying Agent to act on behalf
of the Company, and the Paying Agent is willing to make payments in satisfaction of the Company’s obligations with respect to the Octreotide CCCPs as provided herein. 
  

 1 

 NOW, THEREFORE, in consideration of the premises and mutual agreements herein, the Company and the Paying
Agent hereby agree as follows: 
 Section 1. Appointment of Paying Agent. The Company hereby appoints American Stock
Transfer & Trust Company as the Paying Agent to act as agent for the Company in accordance with the instructions hereinafter set forth in this Agreement, and the Paying Agent hereby accepts such appointment. The Company may from time to
time appoint additional paying agents (“Co-Paying Agent(s)”) as it may deem necessary or desirable. The Paying Agent shall have no duty to supervise, and shall in no event be liable for, the acts or omissions of any such Co-Paying
Agents. In the event of the appointment of a Co-Paying Agent pursuant to this Section 1, the Company shall cause such Co-Paying Agent to become vested with the same powers, rights, duties and responsibilities as if it had originally been named
as Paying Agent. 
 Section 2. No Certificates. The Octreotide CCCPs shall not be evidenced by a certificate or other instrument.

 Section 3. Registration by the Paying Agent. 
 (a) The Company and the Paying Agent may deem and treat the registered holder (the “Holder”) of an Octreotide CCCP as the absolute owner thereof for all purposes, and neither the Company nor the
Paying Agent shall be affected by any notice to the contrary. 
 (b) The Company shall cause to be kept at the Paying Agent’s principal
office a register (the “Octreotide CCCP Register”) in which the Paying Agent shall provide for the registration of the Octreotide CCCPs. The Octreotide CCCPs shall be registered in the names and addresses of, and in the denomination
as set forth in, the applicable letter of transmittal accompanying the shares of Indevus Common Stock surrendered by the holder thereof in connection with the Offer or the Merger pursuant to the Merger Agreement. A Holder may make a written request
to the Paying Agent or the Company to change such Holder’s address of record on the Octreotide CCCP Register. The written request must be duly executed by the Holder. Upon receipt of such written request by the Paying Agent or the Company, the
Paying Agent shall promptly record the change of address on the Octreotide CCCP Register. The Paying Agent shall provide a copy of the Octreotide CCCP Register to the Company upon request. 
 Section 4. Rights of Octreotide CCCP Holder. Nothing contained in this Agreement shall be construed as conferring upon any Holder, by virtue
of being a Holder of an Octreotide CCCP, the right to vote or to consent or to receive notice as stockholders in respect of the meetings of stockholders or the election of directors of the Company or any other matter, or any rights of any kind or
nature whatsoever as a stockholder of the Company, either at law or in equity. The rights of a Holder are limited to those expressed in this Agreement. 
  

 2 

 Section 5. Non-transferability. The Octreotide CCCPs and any interest therein shall not be
sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer (as defined herein) and, in the case of a Permitted Transfer, only in accordance with
Section 6 hereof. A “Permitted Transfer” shall mean (a) the transfer of any or all of the Octreotide CCCPs on death by will or intestacy; (b) transfer by instrument to an inter vivos or testamentary trust in which the
Octreotide CCCPs are to be passed to beneficiaries upon the death of the trustee; (c) transfers made pursuant to a court order of a court of competent jurisdiction (such as in connection with divorce, bankruptcy or liquidation); (d) if the
Holder is a partnership or limited liability company, a distribution by the transferring partnership or limited liability company to its partners or members, as applicable; or (e) a transfer made by operation of law (such as a merger).

 Section 6. Transfer of Octreotide CCCPs. 
 (a) Subject to the restrictions on transferability set forth in Section 5 hereof, the Paying Agent shall, from time to time, register the transfer of any outstanding Octreotide CCCPs upon the Octreotide CCCP
Register, upon delivery to the Paying Agent of a written instrument or instruments of transfer and other requested documentation in a form satisfactory to the Company and the Paying Agent, duly executed by the registered Holder or Holders thereof or
by the duly appointed legal representative thereof or by a duly authorized attorney, such signature to be guaranteed by a participant in a recognized Signature Guarantee Medallion Program. A request for a transfer of an Octreotide CCCP shall be
accompanied by such documentation establishing satisfaction of the conditions set forth in Section 5 hereof as may be reasonably requested by the Company (including opinions of counsel, if appropriate). Upon receipt of documentation reasonably
satisfactory to the Company, the Company shall authorize the Paying Agent to permit the transfer of an Octreotide CCCP. The Paying Agent shall not permit the transfer of an Octreotide CCCP until it is so authorized by the Company. No transfer of an
Octreotide CCCP shall be valid until registered on the Octreotide CCCP Register and any transfer not duly registered on the Octreotide CCCP Register will be void ab initio. All transfers of Octreotide CCCPs registered on the Octreotide CCCP
Register shall be the valid obligations of the Company, representing the same rights to receive cash as the Octreotide CCCPs transferred then entitled such transferee to receive, and shall entitle the transferee to the same benefits and rights under
this Agreement as those held by the transferor. It is clarified that the Octreotide CCCP Register will show one position for Cede & Co which represents all the Shares held by DTC on behalf of the street holders of the Shares as of the
Effective Time and the Paying Agent will have no responsibility whatsoever directly to the street holders with respect to the transfer of Octreotide CCCPs. It is also clarified that with respect to any payments to be made under Section 7 below,
the 

  

 3 

 
Paying Agent will accomplish the payment to the street holders by sending one lump payment to DTC, who will then be required to distribute the payments to
brokers and shareholders as of the Effective Time. The Paying Agent will have no responsibilities whatsoever with regards to distribution of payments to the street holders directly. 
 (b) No service charge shall be made for any registration of transfer of Octreotide CCCPs. The Paying Agent shall have no duty or obligation to take any
action under any Section of this Agreement which requires the payment by a Holder of an Octreotide CCCP of applicable taxes and charges unless and until the Paying Agent is satisfied that all such taxes and/or charges have been paid. 
 Section 7. Payment Procedures. 
 (a) Within 5 business days following the occurrence of the Approval Milestone Date, the Company shall deliver to the Paying Agent (i) a certificate (the “Approval Compliance Certificate”) certifying that the Holders
are entitled to receive the Approval Payment Amount and establishing a payment date with respect to the Approval Payment Amount that is within 5 business days of the issuance of such certificate and (ii) an amount in cash equal to the aggregate
Approval Payment Amount with respect to Octreotide CCCPs held by all Holders. Upon such payment, no further payment by the Company pursuant to this Agreement shall be required. 
 (b) “Approval Milestone Date” shall mean the date on which the Company (or any of its subsidiaries) receives an approval letter from the
U.S. Food and Drug Administration (the “FDA”) with respect to its new drug application for Octreotide (as defined in the Merger Agreement), which approval letter grants the Company the right to market and sell Octreotide immediately
for the treatment of acromegaly or carcinoid syndrome (the “Approval Milestone”) ; provided, however, that, subject to Section 7(k) hereof, if the Approval Milestone Date does not occur on or before the fourth
anniversary of the Offer Closing (the “Approval Deadline”), the Octreotide CCCPs will terminate and all rights thereunder and all rights in respect thereof under this Agreement shall cease. 
 (c) “Approval Payment Amount” means an amount equal to $1.00 per Octreotide CCCP, without interest thereon, payable in cash. 

(d) If (i) prior to the delivery of an Approval Compliance Certificate, events or circumstances occur that cause the Company reasonably to
believe that either or both of the Approval Milestone Date will not and cannot occur prior to the Approval Deadline or, (ii) an approval of Octreotide is obtained but the Company determines that it does not meet the definition of an Approval,
then within 30 days of the occurrence of such events or circumstances or determination, the Company shall 

  

 4 

 
deliver to the Paying Agent a certificate (the “Approval Non-Compliance Certificate”) setting forth in reasonable detail the events and
circumstances underlying its belief that delivery of such Non-Compliance Certificate is required. 
 (e) On the payment date set forth in any
Approval Compliance Certificate, the Paying Agent shall pay the applicable amount to each of the Holders (the amount to which each Holder is entitled to receive will be based on the number of Octreotide CCCPs held by such Holder as reflected on the
Octreotide CCCP Register) by (i) check mailed to the address of each Holder as reflected on the Octreotide CCCP Register as of the close of business on the last business day prior to such Octreotide CCCP Payment Date or (ii) with respect
to Holders that are due Approval Payment Amounts in excess of $1,000,000 in the aggregate who have provided the Company with wire transfer instructions in writing, the Paying Agent will make payments by wire transfer of immediately available funds
to the account specified in the written instructions of the Company. In addition to the notices required by Section 11 hereof, the Company shall cause the Paying Agent, on behalf of and at the expense of the Company, to mail with (or, in the
case of payments made to Holders who have provided the Company with wire instructions, at the same time as) each payment made a copy of the Approval Compliance Certificate. In addition, the Company shall post a copy of such Approval Compliance
Certificate on its Internet website and issue a press release announcing the occurrence of the applicable milestone date. 
 (f) The Company
shall cause the Paying Agent to promptly (and in no event later than five business days after receipt by the Paying Agent) send each Holder a copy of any Non-Compliance Certificate at such Holder’s registered address. 
 (g) The Company shall be entitled to deduct and withhold, or cause to be deducted or withheld, from each Approval Payment Amount otherwise payable
pursuant to this Agreement, such amounts as it is required to deduct and withhold with respect to the making of such payment under the Internal Revenue Code, or any provision of state, local or foreign tax law. To the extent that amounts are so
withheld or paid over to or deposited with the relevant governmental entity, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Holder in respect of which such deduction and withholding was made.

 (h) Any cash that remains undistributed to the Holders of Octreotide CCCPs six months after the payment date set forth in any Approval
Compliance Certificate shall be delivered to the Company, upon demand, and any Holders of Octreotide CCCPs who have not theretofore received cash in exchange for such Octreotide CCCPs shall thereafter look only to the Company for payment of their
claim therefor. Notwithstanding any other provisions of this Agreement, any portion of the cash provided by the Company to the Paying Agent that remains unclaimed after termination of this Agreement in accordance with Section 15 hereof (or such

  

 5 

 
earlier date immediately prior to such time as such amounts would otherwise escheat to, or become property of, any governmental entity) shall, to the extent
permitted by law, become the property of the Company free and clear of any claims or interest of any person previously entitled thereto. 
 (i) The Paying Agent shall keep copies of this Agreement available for inspection by the Holders during normal business hours at its office. The Company shall supply the Paying Agent from time to time with such numbers of copies of this
Agreement as the Paying Agent may request. 
 (j) Any Holder or Holders of at least 20% in the aggregate of the outstanding Octreotide CCCPs
may, within 45 days of receipt of any Non-Compliance Certificate, deliver a written notice to the Paying Agent and the Company stating that such Holder or Holders object to (a “Notice of Objection”) such Non-Compliance Certificate
and setting forth in reasonable detail each of the objections to the events or circumstances described in the applicable Non-Compliance Certificate (collectively, the “Determinations”). If the Company does not agree with the
objections to the applicable Non-Compliance Certificate in the Objection Certificate, the Determinations that are in dispute shall be resolved by the procedure set forth in Section 21, which decision shall be binding on the parties hereto and
the Holders. If no Notice of Objection is delivered to the Paying Agent within such 45 day period, the Approval Payment Amount shall not be due and payable to the Holders, and the Company and the Paying Agent shall have no further obligations with
respect to the Approval Payment Amount. 
 Section 8. Notices to the Company and Paying Agent. Any notice or demand authorized by
this Agreement to be given or made by the Paying Agent or by any Holder to or on the Company shall be sufficiently given or made when received at the office of the Company expressly designated by the Company as its office for purposes of this
Agreement (until the Paying Agent is otherwise notified in accordance with this Section 8 by the Company), as follows: 
 Endo
Pharmaceuticals Holdings Inc. 
 100 Endo Boulevard 
 Chadds Ford, PA 19317 
 Fax No.: (610) 558-9864 
 Attention: Caroline B. Manogue, Esq. 
 and
with a copy to: 
 Skadden, Arps, Slate, Meagher & Flom LLP 
 Four Times Square 
 New York, New York
10036-6522 
 Fax No.: (212) 735-2000 
 Attention: Eileen T. Nugent, Esq. 
  

 6 

 Any notice pursuant to this Agreement to be given by the Company or by any Holder(s) to the Paying Agent
shall be sufficiently given when received by the Paying Agent at the address appearing below (until the Company is otherwise notified in accordance with this Section 8 by the Paying Agent). 
 American Stock Transfer & Trust Company LLC 
 Operations Center 
 6201 15th Avenue 
 Brooklyn, NY 11219 
 Telephone: (800) 937-5449 
 Attention: Reorganization Department 
 Section 9. Supplements and Amendments; Actions. 
 (a) Without the consent of any Holders, the Company, at any time and
from time to time, may enter into one or more amendments hereto, for any of the following purposes: 
 (i) to evidence the
succession of another person to the Company and the assumption by any such successor of the covenants of the Company herein; provided that such succession and assumption is in accordance with the terms of this Agreement; 
 (ii) to evidence the succession of another person as a successor Paying Agent and the assumption by any successor of the covenants and
obligations of such Paying Agent herein; provided that such succession and assumption is in accordance with the terms of this Agreement; 
 (iii) to add to the covenants of the Company such further covenants, restrictions, conditions or provisions as the Company shall consider to be for the protection of Holders; provided that in each case, such
provisions shall not adversely affect the rights of the Holders; or 
 (iv) to cure any ambiguity, to correct or supplement
any provision herein that may be defective or inconsistent with any other provision herein, or to make any other provisions with respect to matters or questions arising under this Agreement; provided that in each case, such provisions shall
not adversely affect the rights of Holders. 
  

 7 

 (b) Subject to Section 9(c) hereof, with the written consent of the Holders of not less than a
majority of the then outstanding and unpaid Octreotide CCCPs delivered to the Company, the Company (when authorized by a Board Resolution (as defined below)) may enter into one or more amendments hereto for the purpose of adding, eliminating or
changing any provision of this Agreement, if such addition, elimination or change is in any way adverse to the rights of Holders. It shall not be necessary for any written consent of Holders under this Section 9(b) to approve the particular
form of any proposed amendment, but it shall be sufficient if such written consent shall approve the substance thereof. “Board Resolution” means a resolution, certified by the secretary or an assistant secretary of the Company to
have been duly adopted by the Board of Directors and to be in full force and effect on the date of such certification, and delivered to the Paying Agent. 
 (c) The unanimous consent of each and every Holder affected shall be required for any amendment pursuant to which the amount of cash payable in consideration for the Octreotide CCCPs would be decreased. 
 (d) Promptly after the execution by the Company of any amendment pursuant to the provisions of this Section 9, the Company shall mail by first class
mail, postage prepaid, a notice thereof to the Holders at their addresses as they shall appear on the Octreotide CCCP Register, setting forth in general terms the substance of such amendment. 
 (e) Upon the execution of any amendment in accordance with this Section 9, this Agreement shall be modified in accordance therewith, such amendment
shall form a part of this Agreement for all purposes and every Holder shall be bound thereby. 
 (f) The Paying Agent shall be entitled to
receive and shall be fully protected in relying upon an officers’ certificate and opinion of counsel as conclusive evidence that any such amendment or supplement is authorized or permitted hereunder, that it is not inconsistent herewith, and
that it will be valid and binding upon the Company in accordance with its terms. 
 Section 10. Enforcement of Rights of Holders.
Any actions seeking enforcement of the rights of Holders hereunder may be brought either by the Paying Agent or the Holders of a majority of outstanding and unpaid Octreotide CCCPs. 
 Section 11. Company May Consolidate, Etc. 
  

 8 

 (a) The Company shall not consolidate with or merge into any other Person (as defined in the Merger
Agreement) or convey, transfer or lease its properties and assets substantially as an entirety to any Person, unless: 
 (i)
The board of directors of the Company shall have determined that, following such transaction, such Person would reasonably be expected to be able to carry out the obligations of the Company hereunder; 
 (ii) the Person formed by such consolidation or into which the Company is merged or the Person that acquires by conveyance or transfer, or
that leases, the properties and assets of the Company substantially as an entirety (the “Surviving Person”) shall, by a supplemental contingent consideration payment agreement or other acknowledgment executed and delivered to the
Paying Agent, expressly assume payment of amounts on all the Octreotide CCCPs and the performance of every duty, obligation liability and covenant of this Agreement, subject to the conditions herein, on the part of the Company to be performed or
observed in the manner prescribed herein; and 
 (iii) the Company has delivered to the Paying Agent a Certificate executed by
the Chief Executive Officer of the Company, stating that such consolidation, merger, conveyance, transfer or lease complies with this Section 11 and that all conditions precedent herein provided for relating to such transaction have been
complied with. 
 (b) Upon any consolidation of or merger by the Company with or into any other Person, or any conveyance, transfer or lease
of the properties and assets substantially as an entirety to any Person in accordance with Section 11(a) hereof, the Surviving Person shall succeed to, and be substituted for, and may exercise every right and power of, the Company under this
Agreement with the same effect as if the Surviving Person had been named as the Company herein, and thereafter, except in the case of a lease, the predecessor Person shall be relieved of all obligations and covenants under this Agreement and the
Octreotide CCCPs. 
 (c) In the event that (i) the Company shall enter into any definitive agreement with respect to a consolidation or
merger (whether by proxy, tender offer or otherwise) involving the Company and for which approval of stockholders of the Company is required, or of the conveyance or transfer of the properties and assets of the Company substantially as an entirety,
or a tender offer or exchange offer for shares of its common stock; or (ii) the Company shall file (or have filed against it) 

  

 9 

 
for the voluntary or involuntary dissolution, liquidation or winding up of the Company, then the Company shall give prompt written notice to the Paying Agent
and shall cause the Paying Agent, on behalf of and at the expense of the Company to give to each Holder of an Octreotide CCCP at his, her or its address appearing on the Octreotide CCCP Register, at least 10 days prior to the applicable record date
for such transaction, or the date of the event in the case of events for which there is no record date, by first-class mail, postage prepaid, a written notice stating (i) the date on which any such consolidation, merger, conveyance, transfer,
dissolution, liquidation or winding up is reasonably expected to become effective or consummated or (ii) the initial expiration date set forth in any tender offer or exchange offer for shares of the Company’s common stock. The failure by
the Company or the Paying Agent to give such notice or any defect therein shall not affect the legality or validity of any consolidation, merger, conveyance, transfer, dissolution, liquidation or winding up, or the vote upon any such action.

 (d) The provisions of this Section 11 shall apply to successive transactions. 
 Section 12. Certain Rights of the Paying Agent. The Paying Agent undertakes the duties and obligations imposed by this Agreement upon the
following terms and conditions, by all of which the Company and the Holders, by their acceptance of the Octreotide CCCPs, shall be bound: 
 (a) The statements contained herein and in any notice delivered by the Company shall be taken as statements of the Company, and the Paying Agent assumes no responsibility for the correctness of any of the same except such as describe the
Paying Agent or any action taken by it. The Paying Agent assumes no responsibility with respect to the distribution of the Octreotide CCCPs except as herein otherwise provided. 
 (b) The Paying Agent shall not be responsible for any failure of the Company to comply with the covenants contained in this Agreement to be complied with
by the Company. The Paying Agent shall not be responsible for the failure of the Company to issue any certificate required under this Agreement or to determine whether such certificate is required or for the contents of any certificate issued by the
Company. 
 (c) The Paying Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder
either by itself (through its employees) or by or through its attorneys or agents (which shall not include its employees) and shall not be responsible for the misconduct of any agent appointed with due care. 
  

 10 

 (d) The Paying Agent may consult at any time with legal counsel satisfactory to it (who may be counsel
for the Company), and the Paying Agent shall incur no liability or responsibility to the Company or to any Holder in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with the opinion or the advice of
such counsel. 
 (e) Whenever in the performance of its duties under this Agreement the Paying Agent shall deem it necessary or desirable
that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless such evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively
proved and established by a certificate signed by the Chairman of the Board, the Chief Executive Officer, the President, the Chief Financial Officer, one of the Vice Presidents, the Treasurer or the Secretary of the Company and delivered to the
Paying Agent; and such certificate shall be full authorization to the Paying Agent for any action taken or suffered in good faith by it under the provisions of this Agreement in reliance upon such certificate. 
 (f) The Company agrees to pay the Paying Agent reasonable compensation for all services rendered by the Paying Agent in the performance of its duties
under this Agreement, to reimburse the Paying Agent for all expenses, taxes and governmental charges and other charges of any kind and nature incurred by the Paying Agent (including reasonable fees and expenses of the Paying Agent’s counsel and
agents) in the performance of its duties under this Agreement, and to indemnify the Paying Agent and save it harmless against any and all liabilities, including judgments, costs and counsel fees, for anything done or omitted by the Paying Agent in
the performance of its duties under this Agreement, except as a result of the Paying Agent’s gross negligence or bad faith. 
 (g) The
Paying Agent shall be under no obligation to institute any action, suit or legal proceeding or to take any other action likely to involve expense unless the Company or one or more Holders shall furnish the Paying Agent with reasonable security and
indemnity satisfactory to the Paying Agent for any costs and expenses which may be incurred, but this provision shall not affect the power of the Paying Agent to take such action as the Paying Agent may consider proper, whether with or without any
such security or indemnity. All rights of action under this Agreement may be enforced by the Paying Agent, and any such action, suit or proceeding instituted by the Paying Agent shall be brought in its name as Paying Agent, and any recovery of
judgment shall be for the ratable benefit of the Holders, as their respective rights or interests may appear. 
 (h) The Paying Agent and any
stockholder, director, officer or employee of the Paying Agent may buy, sell or deal in any other securities of the Company or become pecuniarily interested in any transactions in which the Company may be 

  

 11 

 
interested, or contract with or lend money to the Company or otherwise act as fully and freely as though it were not Paying Agent under this Agreement or
such director, officer or employee. Nothing herein shall preclude the Paying Agent from acting in any other capacity for the Company or for any other legal entity including, without limitation, acting as transfer agent or as a lender to the Company
or an affiliate thereof. 
 (i) The Paying Agent shall act hereunder solely as agent, and its duties shall be determined solely by the
provisions hereof. The Paying Agent shall not be liable for anything which it may do or refrain from doing in connection with this Agreement except for its own gross negligence or bad faith. 
 (j) The Paying Agent will not incur any liability or responsibility to the Company or to any Holder for any action taken in reliance on any notice,
resolution, waiver, consent, order, certificate, or other paper, document or instrument reasonably believed by it to be genuine and to have been signed, sent or presented by the proper party or parties. 
 (k) The Paying Agent shall not be under any responsibility in respect of the validity of this Agreement or the execution and delivery hereof (except the
due execution hereof by the Paying Agent) or in respect of the validity of any Octreotide CCCP. 
 (l) The Paying Agent is hereby authorized
and directed to accept instructions with respect to the performance of its duties hereunder from the Chairman of the Board, the Chief Executive Officer President, the Chief Financial Officer, any Vice President or the Secretary of the Company, and
to apply to such officers for advice or instructions in connection with its duties, and shall not be liable for any action taken or suffered to be taken by it in good faith and without negligence in accordance with the instructions of any such
officer or officers. 
 Section 13. Designation; Removal; Successor Paying Agent. The Paying Agent may resign at any time and be
discharged from its duties under this Agreement by giving to the Company 30 days notice in writing. The Company may remove the Paying Agent or any successor Paying Agent by giving to the Paying Agent or successor Paying Agent 30 days notice in
writing. If the Paying Agent shall resign or be removed or shall otherwise become incapable of acting, the Company shall appoint a successor to the Paying Agent. If the Company shall fail to make such appointment within a period of 30 days after
such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Paying Agent or by any Holder (whose name shall appear on the Octreotide CCCP Register), then any Holder may apply to any court
of competent jurisdiction for the appointment of a successor to the Paying Agent. Pending 

  

 12 

 
appointment of a successor Paying Agent, either by the Company or by such court, the duties of the Paying Agent shall be carried out by the Company. Any
successor Paying Agent, whether appointed by the Company or such a court, shall be a bank or trust company in good standing, incorporated under the laws of the United States of America or any State thereof or the District of Columbia and having at
the time of its appointment as Paying Agent a combined capital and surplus of at least $10,000,000. After appointment, the successor Paying Agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally
named as Paying Agent without further act or deed; but the former Paying Agent shall deliver and transfer to the successor Paying Agent any property at the time held by it hereunder, and execute and deliver any further assurance, conveyance, act or
deed necessary for such purpose. In the event of such resignation or removal, the Company or the successor Paying Agent shall mail by first class mail, postage prepaid, to each Holder, written notice of such removal or resignation and the name and
address of such successor Paying Agent. Failure to file any notice provided for in this Section 13, however, or any defect therein, shall not affect the legality or validity of the resignation or removal of the Paying Agent or the appointment
of the successor Paying Agent, as the case may be. 
 Section 14. Successors. All the covenants and provisions of this Agreement
by or for the benefit of the Company, the Paying Agent or any Holder shall bind and inure to the benefit of their respective successors, assigns, heirs and personal representatives. 
 Section 15. Termination; Effect of Termination. 
 (a) Subject to the resolution of any disputes in accordance with Sections 7(k) and 21 hereof, in the event that the Approval Milestone Date shall not have occurred on or prior to the Approval Deadline, this Agreement
shall terminate at 5:00 p.m., New York City time, on the Approval Deadline. 
 (b) In the event that the Approval Milestone Date shall have
occurred prior to the Approval Deadline, this Agreement will terminate at 5:00 p.m., New York City time, on the date that all payments are sent by the Paying Agent in respect of the payment date set forth in any certificate delivered pursuant to
Section 7(a) hereof. 
 Section 16. Governing Law. This Agreement shall be governed by, and construed in accordance with,
the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflict of laws thereof. 
  

 13 

 Section 17. Benefits of this Agreement. Nothing in this Agreement shall be construed to give
to any person or corporation other than the Company, the Paying Agent and the Holders any legal or equitable right, remedy or claim under this Agreement; but this Agreement shall be for the sole and exclusive benefit of the Company, the Paying Agent
and the Holders. 
 Section 18. Counterparts. This Agreement may be executed in two or more counterparts, all of which shall be
considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other parties. 
 Section 19. Headings. The headings and table of contents contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

 Section 20. Additional Covenants. 
 (a) List of Holders. The Company shall furnish or cause to be furnished to the Paying Agent (a) in such form as the Company receives from its transfer agent (or other agent performing similar services for
the Company), the names and addresses of the Holders within five business days of the Effective Time, and (b) at such times as the Paying Agent may request in writing, within five business days after receipt by the Company of any such request,
a list, in such form as the Company receives from its transfer agent (or other agent performing similar services for the Company), of the names and the addresses of the Holders as of a date not more than 15 days prior to the time such list is
furnished. 
 (b) Ability To Make Prompt Payment. Neither the Company nor any of its subsidiaries shall enter into any
agreement that would restrict the Company’s right to be able to promptly make or cause to be made payments to the Holders under this Agreement or otherwise restrict the Company’s ability to fund or cause to be funded such payments.

 Section 21. Negotiation; Arbitration. 
 (a) Prior to any arbitration pursuant to Section 21(b) hereof, the Company, the Paying Agent and any Holder or Holders of at least 20% in the aggregate of the outstanding Octreotide CCCPs shall negotiate in good
faith for a period of 30 days to resolve any controversy or claim arising out of or relating to this Agreement, or the alleged breach thereof. 
 (b) After expiration of the 30-day period contemplated by Section 21(a) hereof, such controversy or claim, including any claims for breach of this Agreement, shall be settled by arbitration administered by the American Arbitration

  

 14 

 
Association under its Commercial Arbitration Rules, and judgment on the award rendered by the arbitrators may be entered in any court having jurisdiction
thereof. The Company, the Paying Agent and any Holder or Holders of at least 20% in the aggregate of the outstanding Octreotide CCCPs may initiate an arbitration for any matter relating to this Agreement. The number of arbitrators shall be three.
Within 15 days after the commencement of arbitration, each party shall select one person to act as arbitrator, and the two selected shall select a third arbitrator within 15 days of their appointment. If the arbitrators selected by the parties are
unable or fail to agree upon the third arbitrator, the third arbitrator shall be selected by the American Arbitration Association. The place of the arbitration shall be New York, New York, and the arbitration shall be conducted in such a manner so
that the written opinion of the arbitrators is given within 180 days after the arbitrators are selected. The arbitrators shall be lawyers or retired judges with experience in the life sciences industry and with mergers and acquisitions. Except as
may be required by law, neither a party nor an arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both parties. All fees and expenses incurred in connection with any
arbitration, including the costs and expenses billed by the arbitrators in connection with the performance of their duties described herein shall be paid by the party or parties against whom the arbitrators rule. 
 Any award payable in favor of the Holder or Paying Agent as a result of arbitration shall be distributed to the Holders on a pro rata basis, based on the
number of Octreotide CCCPs held by each Holder. 
  

 15 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed, as of the day and
year first above written. 
  

			
	ENDO PHARMACEUTICALS HOLDINGS INC.
		
	By:	 	 /s/ David P. Holveck

	Name:	 	David P. Holveck
	Title:	 	CEO
	
	AMERICAN STOCK TRANSFER & TRUST COMPANY
	
	as Paying Agent
		
	By:	 	 /s/ Isaac Freilich

	Name:	 	Isaac Freilich
	Title:	 	VP

  

 16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}]]